{"componentChunkName":"component---src-templates-topic-topic-tsx","path":"/topics/dyspepsia-proven-peptic-ulcer/","result":{"data":{"firstChapter":{"id":"b126bb0b-6cc6-5fb5-a165-08590aab0070","slug":"summary","fullItemName":"Summary","subChapters":[],"depth":1,"htmlHeader":"<!-- begin field d478c3e4-3066-4b15-9503-26075790387c --><h1>Dyspepsia - proven peptic ulcer: Summary</h1><!-- end field d478c3e4-3066-4b15-9503-26075790387c -->","htmlStringContent":"<!-- begin item 15e492e7-2e02-48f0-8bc0-1d1d464ad944 --><!-- begin field e283c0d7-a83f-432e-9045-af09ec817875 --><ul><li>The term 'dyspepsia' is used to describe a complex of upper gastrointestinal tract symptoms which are typically present for four or more weeks, including upper abdominal pain or discomfort, heartburn, acid reflux, nausea and/or vomiting.<ul><li>If symptoms of heartburn and acid regurgitation predominate, then gastro-oesophageal reflux disease (GORD) is the more likely diagnosis.</li></ul></li><li>Gastric or duodenal ulcers (peptic ulcer disease) describe a breach in the epithelium of the gastric or duodenal mucosa, which is confirmed on endoscopy.</li><li>The most common risk factors for the development of peptic ulcer disease are <em>Helicobacter pylori</em> infection and nonsteroidal anti-inflammatory drugs (NSAIDs) or aspirin.</li><li>Complications of peptic ulcer disease include haemorrhage, perforation, and gastric outlet obstruction.</li><li>Initial management of peptic ulcer disease includes:<ul><li>Offering advice on lifestyle modification.</li><li>Assessing for stress, anxiety, and depression.</li><li>Reviewing and stopping any drugs which may be exacerbating symptoms.</li></ul></li><li>Testing for <em>H. pylori </em>infection should be arranged if the person's status is not known or uncertain.<ul><li>Ideally, a carbon-13 urea breath test or stool antigen test should be used — ensuring the person has not taken a proton pump inhibitor (PPI) in the past 2 weeks, or antibiotics in the past 4 weeks.</li><li>If the test is positive (with NSAID use), a full-dose proton pump inhibitor (PPI) should be prescribed for 2 months, followed by first-line <em>H. pylori</em> eradication therapy. If there is no associated NSAID use, eradication therapy should be offered.</li><li>If the test is negative, full-dose PPI therapy should be offered for 4–8 weeks.</li></ul></li><li>All people with a proven gastric ulcer should have a repeat endoscopy arranged and <em>H. pylori</em> re-testing (if appropriate) 6–8 weeks after starting treatment.<ul><li>If the test is positive, second-line <em>H. pylori</em> eradication therapy should be offered.</li><li>NSAIDs or aspirin should be stopped, if possible and appropriate.</li><li>A low-dose PPI or standard-dose histamine (H<sub>2</sub>)-receptor antagonist (H<sub>2</sub>RA) should be offered as needed.</li><li>Long-term acid suppression therapy can be considered.</li></ul></li><li>All people with a proven duodenal ulcer who have refractory or recurrent symptoms should have <em>H. pylori</em> re-testing 6–8 weeks after starting treatment (if this was needed).<ul><li>If the test is positive, second-line <em>H. pylori</em> eradication therapy should be offered.</li><li>If initial testing was negative and there are ongoing symptoms, other causes of duodenal ulcer should be considered.</li><li>A low-dose PPI or standard-dose H<sub>2</sub>RA should be offered as needed.</li><li>Long-term acid suppression therapy can be considered.</li></ul></li><li>People on long-term treatment for peptic ulcer disease should be:<ul><li>Offered an annual review.</li><li>Encouraged to step down or stop treatment, if possible and appropriate.</li></ul></li><li>Referral to a gastroenterologist should be considered if:<ul><li>There are refractory or recurrent symptoms despite optimal management in primary care.</li><li>Treatment with a second-line <em>H. pylori</em> eradication regimen has been unsuccessful.</li><li>There are limited antibiotic options for <em>H. pylori</em> eradication therapy.</li><li>A proven gastric ulcer has not healed on repeat endoscopy.</li><li>A non-peptic cause of ulcer disease is suspected.</li></ul></li></ul><!-- end field e283c0d7-a83f-432e-9045-af09ec817875 --><!-- end item 15e492e7-2e02-48f0-8bc0-1d1d464ad944 -->","topic":{"id":"4d7c8c68-3a8f-5975-99a6-50cb32ce9c94","topicId":"3ad099a3-2ca3-4327-9bda-99105ccbd251","topicName":"Dyspepsia - proven peptic ulcer","slug":"dyspepsia-proven-peptic-ulcer","aliases":[],"chapters":[{"id":"b126bb0b-6cc6-5fb5-a165-08590aab0070","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"7966dab4-9ee2-5d7d-8253-890904345546","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"863af072-467d-558f-a5a4-938251ca4b70","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"c6e3fda6-22f9-51b3-94d8-fc248cda56bd","slug":"changes","fullItemName":"Changes"},{"id":"d90954aa-bfcf-53f9-bf54-94b6f90fc75f","slug":"update","fullItemName":"Update"}]},{"id":"b8e40cd5-8e95-5335-9d56-292936d0d7a7","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"b8925c36-3dae-5ec7-8277-83b343cdc753","slug":"goals","fullItemName":"Goals"},{"id":"99d05347-f238-52f8-a91d-6367fc2a4c84","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2658a735-068a-5b5a-b9de-83da5c0d4c04","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6e095fbb-fc3e-5b4e-aec2-bf80df353e31","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"90cb6b5a-e54b-565d-809f-76ac723d4bba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a584a99-78fc-5b5b-8ae6-b14250c00325","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"df3e0e6a-10b7-5ced-9c05-dff646629460","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"f35e4de1-c942-50cb-aef3-91b3c4def480","slug":"definition","fullItemName":"Definition"},{"id":"a8810be9-e85c-535f-9ccd-50aee78e9c8b","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"da86cd41-e515-572c-aa44-9330eba9ac28","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f5dd15bb-7399-5245-8f59-87a9790a59a7","slug":"complications","fullItemName":"Complications"},{"id":"126a2719-f8ba-5188-ac87-dcecfe57ea0e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"6278e7c4-7eeb-5045-b77c-00b84f08b040","slug":"management","fullItemName":"Management","subChapters":[{"id":"be22af5a-19ce-5791-8415-1297662b5e10","slug":"management-proven-peptic-ulcer","fullItemName":"Scenario: Management - proven peptic ulcer"}]},{"id":"6dc780ed-17b4-53f7-b5b1-9ce5899e505f","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"967aa284-35b6-5f7c-838f-5dbbda36ac93","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"e2e731b3-6cb9-5268-b8c9-9839738dcf7f","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"59f31401-2de6-5276-9ffc-800e8e519e95","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"9eb0d371-d052-5fd9-ba58-45fcf40cbbfe","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"d2ff9ee7-1022-5cb2-aa78-f65bf08be543","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"b8602cfd-a10c-5663-b691-a8ca11b0ed81","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"f17ce37f-6d62-5780-b8d9-9426dcd13e56","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"9eb2f48d-68e2-51ca-acee-8ae753fa0e83","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"5d80e758-2b4f-50bd-957d-658701dadd77","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"5d902b88-104e-572b-9dcd-f4035f35a4c5","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"b954b837-c685-5f3f-b569-e2a1cc897ef4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f1ddadd9-ccea-5965-9c2f-6e2848db1f33","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"49079197-90f7-5a71-9f31-cd48ba3d7e9b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"201aafd4-5cd3-5f8d-9ac0-364e8cd95e53","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ea362840-d561-5944-8292-1f1c7a1feef4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c1e4fdd8-fd8a-5191-aaf4-fb43c1ed5a7f","slug":"references","fullItemName":"References","subChapters":[]}]}},"topic":{"id":"4d7c8c68-3a8f-5975-99a6-50cb32ce9c94","topicId":"3ad099a3-2ca3-4327-9bda-99105ccbd251","topicName":"Dyspepsia - proven peptic ulcer","slug":"dyspepsia-proven-peptic-ulcer","aliases":[],"topicSummary":"The term 'dyspepsia' is used to describe a complex of upper gastrointestinal tract symptoms","lastRevised":"Last revised in October 2019","nextPlannedReviewBy":"2022-10-01T00:00:00+01:00","nextPlannedReviewByDateTime":"2022-09","nextPlannedReviewByDisplay":"September 2022","specialities":[{"id":"e4fd15e3-ef70-523f-843c-5270742f518d","name":"Gastrointestinal","slug":"gastrointestinal"}],"chapters":[{"id":"b126bb0b-6cc6-5fb5-a165-08590aab0070","slug":"summary","fullItemName":"Summary","subChapters":[]},{"id":"7966dab4-9ee2-5d7d-8253-890904345546","slug":"have-i-got-the-right-topic","fullItemName":"Have I got the right topic?","subChapters":[]},{"id":"863af072-467d-558f-a5a4-938251ca4b70","slug":"how-up-to-date-is-this-topic","fullItemName":"How up-to-date is this topic?","subChapters":[{"id":"c6e3fda6-22f9-51b3-94d8-fc248cda56bd","slug":"changes","fullItemName":"Changes"},{"id":"d90954aa-bfcf-53f9-bf54-94b6f90fc75f","slug":"update","fullItemName":"Update"}]},{"id":"b8e40cd5-8e95-5335-9d56-292936d0d7a7","slug":"goals-outcome-measures","fullItemName":"Goals and outcome measures","subChapters":[{"id":"b8925c36-3dae-5ec7-8277-83b343cdc753","slug":"goals","fullItemName":"Goals"},{"id":"99d05347-f238-52f8-a91d-6367fc2a4c84","slug":"outcome-measures","fullItemName":"Outcome measures"},{"id":"2658a735-068a-5b5a-b9de-83da5c0d4c04","slug":"audit-criteria","fullItemName":"Audit criteria"},{"id":"6e095fbb-fc3e-5b4e-aec2-bf80df353e31","slug":"qof-indicators","fullItemName":"QOF indicators"},{"id":"90cb6b5a-e54b-565d-809f-76ac723d4bba","slug":"qipp-options-for-local-implementation","fullItemName":"QIPP - Options for local implementation"},{"id":"3a584a99-78fc-5b5b-8ae6-b14250c00325","slug":"nice-quality-standards","fullItemName":"NICE quality standards"}]},{"id":"df3e0e6a-10b7-5ced-9c05-dff646629460","slug":"background-information","fullItemName":"Background information","subChapters":[{"id":"f35e4de1-c942-50cb-aef3-91b3c4def480","slug":"definition","fullItemName":"Definition"},{"id":"a8810be9-e85c-535f-9ccd-50aee78e9c8b","slug":"risk-factors","fullItemName":"Risk factors"},{"id":"da86cd41-e515-572c-aa44-9330eba9ac28","slug":"prevalence","fullItemName":"Prevalence"},{"id":"f5dd15bb-7399-5245-8f59-87a9790a59a7","slug":"complications","fullItemName":"Complications"},{"id":"126a2719-f8ba-5188-ac87-dcecfe57ea0e","slug":"prognosis","fullItemName":"Prognosis"}]},{"id":"6278e7c4-7eeb-5045-b77c-00b84f08b040","slug":"management","fullItemName":"Management","subChapters":[{"id":"be22af5a-19ce-5791-8415-1297662b5e10","slug":"management-proven-peptic-ulcer","fullItemName":"Scenario: Management - proven peptic ulcer"}]},{"id":"6dc780ed-17b4-53f7-b5b1-9ce5899e505f","slug":"prescribing-information","fullItemName":"Prescribing information","subChapters":[{"id":"967aa284-35b6-5f7c-838f-5dbbda36ac93","slug":"proton-pump-inhibitors","fullItemName":"Proton pump inhibitors"},{"id":"e2e731b3-6cb9-5268-b8c9-9839738dcf7f","slug":"h2-receptor-antagonists","fullItemName":"H2-receptor antagonists"},{"id":"59f31401-2de6-5276-9ffc-800e8e519e95","slug":"amoxicillin","fullItemName":"Amoxicillin"},{"id":"9eb0d371-d052-5fd9-ba58-45fcf40cbbfe","slug":"clarithromycin","fullItemName":"Clarithromycin"},{"id":"d2ff9ee7-1022-5cb2-aa78-f65bf08be543","slug":"metronidazole","fullItemName":"Metronidazole"},{"id":"b8602cfd-a10c-5663-b691-a8ca11b0ed81","slug":"tetracycline","fullItemName":"Tetracycline"},{"id":"f17ce37f-6d62-5780-b8d9-9426dcd13e56","slug":"levofloxacin","fullItemName":"Levofloxacin"},{"id":"9eb2f48d-68e2-51ca-acee-8ae753fa0e83","slug":"bismuth","fullItemName":"Bismuth"}]},{"id":"5d80e758-2b4f-50bd-957d-658701dadd77","slug":"supporting-evidence","fullItemName":"Supporting evidence","subChapters":[]},{"id":"5d902b88-104e-572b-9dcd-f4035f35a4c5","slug":"how-this-topic-was-developed","fullItemName":"How this topic was developed","subChapters":[{"id":"b954b837-c685-5f3f-b569-e2a1cc897ef4","slug":"search-strategy","fullItemName":"Search strategy"},{"id":"f1ddadd9-ccea-5965-9c2f-6e2848db1f33","slug":"stakeholder-engagement","fullItemName":"Stakeholder engagement"},{"id":"49079197-90f7-5a71-9f31-cd48ba3d7e9b","slug":"evidence-exclusion-criteria","fullItemName":"Evidence exclusion criteria"},{"id":"201aafd4-5cd3-5f8d-9ac0-364e8cd95e53","slug":"organizational-behavioural-financial-barriers","fullItemName":"Organizational, behavioural and financial barriers"},{"id":"ea362840-d561-5944-8292-1f1c7a1feef4","slug":"declarations-of-interest","fullItemName":"Declarations of interest"}]},{"id":"c1e4fdd8-fd8a-5191-aaf4-fb43c1ed5a7f","slug":"references","fullItemName":"References","subChapters":[]}]}},"pageContext":{"id":"4d7c8c68-3a8f-5975-99a6-50cb32ce9c94"}},"staticQueryHashes":["3666801979"]}